Cargando…
Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots
As the coronavirus disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide, it has emerged as a leading cause of mortality, resulting in >1 million deaths over the past 10 months. The pathophysiology of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882149/ https://www.ncbi.nlm.nih.gov/pubmed/33615129 http://dx.doi.org/10.1093/rap/rkaa081 |
_version_ | 1783651002587545600 |
---|---|
author | Tung, Moon Ley Tan, Bryce Cherian, Robin Chandra, Bharatendu |
author_facet | Tung, Moon Ley Tan, Bryce Cherian, Robin Chandra, Bharatendu |
author_sort | Tung, Moon Ley |
collection | PubMed |
description | As the coronavirus disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide, it has emerged as a leading cause of mortality, resulting in >1 million deaths over the past 10 months. The pathophysiology of COVID-19 remains unclear, posing a great challenge to the medical management of patients. Recent studies have reported an unusually high prevalence of thromboembolic events in COVID-19 patients, although the mechanism remains elusive. Several studies have reported the presence of aPLs in COVID-19 patients. We have noticed similarities between COVID-19 and APS, which is an autoimmune prothrombotic disease that is often associated with an infective aetiology. Molecular mimicry and endothelial dysfunction could plausibly explain the mechanism of thrombogenesis in acquired APS. In this review, we discuss the clinicopathological similarities between COVID-19 and APS, and the potential role of therapeutic targets based on the anti-phospholipid model for COVID-19 disease. |
format | Online Article Text |
id | pubmed-7882149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-78821492021-02-18 Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots Tung, Moon Ley Tan, Bryce Cherian, Robin Chandra, Bharatendu Rheumatol Adv Pract Review As the coronavirus disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide, it has emerged as a leading cause of mortality, resulting in >1 million deaths over the past 10 months. The pathophysiology of COVID-19 remains unclear, posing a great challenge to the medical management of patients. Recent studies have reported an unusually high prevalence of thromboembolic events in COVID-19 patients, although the mechanism remains elusive. Several studies have reported the presence of aPLs in COVID-19 patients. We have noticed similarities between COVID-19 and APS, which is an autoimmune prothrombotic disease that is often associated with an infective aetiology. Molecular mimicry and endothelial dysfunction could plausibly explain the mechanism of thrombogenesis in acquired APS. In this review, we discuss the clinicopathological similarities between COVID-19 and APS, and the potential role of therapeutic targets based on the anti-phospholipid model for COVID-19 disease. Oxford University Press 2021-02-04 /pmc/articles/PMC7882149/ /pubmed/33615129 http://dx.doi.org/10.1093/rap/rkaa081 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Tung, Moon Ley Tan, Bryce Cherian, Robin Chandra, Bharatendu Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots |
title | Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots |
title_full | Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots |
title_fullStr | Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots |
title_full_unstemmed | Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots |
title_short | Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots |
title_sort | anti-phospholipid syndrome and covid-19 thrombosis: connecting the dots |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882149/ https://www.ncbi.nlm.nih.gov/pubmed/33615129 http://dx.doi.org/10.1093/rap/rkaa081 |
work_keys_str_mv | AT tungmoonley antiphospholipidsyndromeandcovid19thrombosisconnectingthedots AT tanbryce antiphospholipidsyndromeandcovid19thrombosisconnectingthedots AT cherianrobin antiphospholipidsyndromeandcovid19thrombosisconnectingthedots AT chandrabharatendu antiphospholipidsyndromeandcovid19thrombosisconnectingthedots |